← FDA DRUG APPROVALS

FDA BLA · BLA761339

VEOPOZ

pozelimab

Sponsor: REGENERON PHARMACEUTICALS

APPLICATION
BLA761339
TYPE
BLA
ORIGINAL APPROVAL
2023-08-18
LATEST ACTION
2023-08-18
ROUTE
INTRAVENOUS, SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

VEOPOZPrescription
POZELIMAB-BBFG 400MG/2ML(200MG/ML) · INJECTABLE · INJECTION

Approval history

2023-08-18Type 1 - New Molecular Entity · Original · priorityLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →